Vivos Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Vivos Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Vivos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$2.62M, a 25% decline year-over-year.
  • Vivos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$12.6M, a 18.5% increase year-over-year.
  • Vivos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$13.6M, a 43% increase from 2022.
  • Vivos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$23.8M, a 17.5% decline from 2021.
  • Vivos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$20.3M, a 68.3% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$12.6M -$2.62M -$523K -25% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$12M -$1.93M +$3.6M +65.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$15.6M -$3.76M -$2.06M -121% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$13.6M -$4.26M +$1.83M +30% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-07-30
Q3 2023 -$15.4M -$2.09M +$3.34M +61.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$18.8M -$5.53M +$1.46M +20.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$20.2M -$1.7M +$3.63M +68.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$23.8M -$6.09M +$1.31M +17.7% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-07-30
Q3 2022 -$25.2M -$5.43M +$19K +0.35% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$25.2M -$6.99M -$2.95M -72.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$22.2M -$5.33M -$1.93M -56.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$20.3M -$7.39M -$1.14M -18.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$19.1M -$5.45M -$3.64M -201% Jul 1, 2021 Sep 30, 2021 10-Q 2022-12-20
Q2 2021 -$15.5M -$4.04M -$2.63M -186% Apr 1, 2021 Jun 30, 2021 10-Q 2022-12-20
Q1 2021 -$12.9M -$3.4M -$818K -31.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-12-20
Q4 2020 -$12.1M -$6.25M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$1.81M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$1.41M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$2.58M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.